10 Firms End 2024 Stronger With Impressive Gains

7. Geron Corp. (NASDAQ:GERN)

Geron Corp. rose for a third day on Wednesday, ending the year stronger by 4.12 percent at $3.54 apiece. Year-to-date, the company eked out gains of 65.4 percent from the $2.14 registered on January 2, 2024.

Based on three continuous days of rally, investors resorted to buying while waiting for fresh developments about its business updates.

Just recently, the company announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of its drug Rytelo for treating specific types of myelodysplastic syndromes (MDS).

The recommendation is expected to be endorsed by the European Commission, with a final decision on market authorization expected in the coming months.

Geron Corporation is a late-stage clinical biopharmaceutical company that focuses on developing and commercializing therapeutics for myeloid hematologic malignancies. The company’s lead product, Imetelstat, effectively treats MDS and myelofibrosis (MF). Consequently, the company is well-positioned to be a key player in the oncology market.